GenoMed® (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company, announced today that its cure for 90% of chronic kidney disease has been picked up by Reuter's after nearly 6 years: The Centers for Medicaid and Medicare (CMS) currently pay $25 billion annually for kidney dialysis and transplantation. A typical dialysis patient costs $100,000 a year, and lives less than 5 years. When GenoMed's CEO, Dr. David Moskowitz, briefed CMS in 2004, the Medical Director of CMS had no interest. Neither has CMS's subsequent Medical Director, who, ironically, is a kidney specialist. Nor did the National Institutes of Health, nor any... ......
Read More